Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trials

References

• Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68(Suppl 8):17–25.
   PubMed Web of Science ®Google Scholar
• Smagula SF, Butters MA, Anderson SJ, et al. Antidepressant response trajectories and associated clinical prognostic factors among older adults. JAMA Psychiatry. 2015;72(10):1021–1028.
   PubMed Web of Science ®Google Scholar
• Khan A, Fahl Mar K, Faucett J, et al. Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013. World Psychiatry. 2017;16(2):181–192.
   PubMed Web of Science ®Google Scholar
• Cassano GB, Baldini Rossi N, Pini S. Psychopharmacology of anxiety disorders. Dialogues Clin Neurosci. 2002;4(3):271–285.
   PubMedGoogle Scholar
• Morin CM, Jarrin DC, Ivers H, et al. Incidence, persistence, and remission rates of insomnia over 5 years. JAMA Netw Open. 2020;3(11):e2018782.
   PubMed Web of Science ®Google Scholar
• Braden JB, Sullivan MD, Ray GT, et al. Trends in long-term opioid therapy for noncancer pain among persons with a history of depression. Gen Hosp Psychiatry. 2009;31(6):564–570.
   PubMed Web of Science ®Google Scholar
• Burston JJ, Valdes AM, Woodhams SG, et al. The impact of anxiety on chronic musculoskeletal pain and the role of astrocyte activation. Pain. 2019;160(3):658–669.
   PubMed Web of Science ®Google Scholar
• Conner TS, Tennen H, Zautra AJ, et al. Coping with rheumatoid arthritis pain in daily life: within-person analyses reveal hidden vulnerability for the formerly depressed. Pain. 2006;126(1–3):198–209.
   PubMed Web of Science ®Google Scholar
• Koffel E, Kats AM, Kroenke K, et al. Sleep disturbance predicts less improvement in pain outcomes: secondary analysis of the SPACE randomized clinical trial. Pain Med. 2020;21(6):1162–1167.
   PubMed Web of Science ®Google Scholar
• Taylor SS, Hughes JM, Coffman CJ, et al. Prevalence of and characteristics associated with insomnia and obstructive sleep apnea among veterans with knee and hip osteoarthritis. BMC Musculoskelet Disord. 2018;19(1):79.
   PubMed Web of Science ®Google Scholar
• Tennen H, Affleck G, Zautra A. Depression history and coping with chronic pain: a daily process analysis. Health Psychol. 2006;25(3):370–379.
   PubMed Web of Science ®Google Scholar
• Woo AK. Depression and anxiety in pain. Rev Pain. 2010;4(1):8–12.
   PubMedGoogle Scholar
• Stubbs B, Aluko Y, Myint PK, et al. Prevalence of depressive symptoms and anxiety in osteoarthritis: a systematic review and meta-analysis. Age Ageing. 2016;45(2):228–235.
   PubMed Web of Science ®Google Scholar
• Agarwal P, Sambamoorthi U. Healthcare expenditures associated with depression among individuals with osteoarthritis: post-regression linear decomposition approach. J Gen Intern Med. 2015;30(12):1803–1811.
   PubMed Web of Science ®Google Scholar
• Nazarinasab M, Motamedfar A, Moqadam AE. Investigating mental health in patients with osteoarthritis and its relationship with some clinical and demographic factors. Reumatologia. 2017;55(4):183–188.
   PubMedGoogle Scholar
• Liu M, McCurry SM, Belza B, et al. Effects of osteoarthritis pain and concurrent insomnia and depression on health care use in a primary care population of older adults. Arthritis Care Res (Hoboken). 2019;71(6):748–757.
   PubMed Web of Science ®Google Scholar
• Rosemann T, Laux G, Kuehlein T. Osteoarthritis and functional disability: results of a cross sectional study among primary care patients in Germany. BMC Musculoskelet Disord. 2007;8(1):79.
   PubMed Web of Science ®Google Scholar
• Zullig LL, Bosworth HB, Jeffreys AS, et al. The association of comorbid conditions with patient-reported outcomes in veterans with hip and knee osteoarthritis. Clin Rheumatol. 2015;34(8):1435–1441.
   PubMed Web of Science ®Google Scholar
• Sharma A, Kudesia P, Shi Q, et al. Anxiety and depression in patients with osteoarthritis: impact and management challenges. Open Access Rheumatol. 2016;8:103–113.
   PubMedGoogle Scholar
• Wilcox S, Brenes GA, Levine D, et al. Factors related to sleep disturbance in older adults experiencing knee pain or knee pain with radiographic evidence of knee osteoarthritis. J Am Geriatr Soc. 2000;48(10):1241–1251.
   PubMed Web of Science ®Google Scholar
• Mallen CD, Nicholl BI, Lewis M, et al. The effects of implementing a point-of-care electronic template to prompt routine anxiety and depression screening in patients consulting for osteoarthritis (the Primary Care Osteoarthritis Trial): a cluster randomised trial in primary care. PLoS Med. 2017;14(4):e1002273.
   PubMed Web of Science ®Google Scholar
• Campbell CM, Buenaver LF, Finan P, et al. Sleep, pain catastrophizing, and central sensitization in knee osteoarthritis patients with and without insomnia. Arthritis Care Res (Hoboken). 2015;67(10):1387–1396.
   PubMed Web of Science ®Google Scholar
• Pinto PR, McIntyre T, Ferrero R, et al. Predictors of acute postsurgical pain and anxiety following primary total hip and knee arthroplasty. J Pain. 2013;14(5):502–515.
   PubMed Web of Science ®Google Scholar
• Lopez-Olivo MA, Landon GC, Siff SJ, et al. Psychosocial determinants of outcomes in knee replacement. Ann Rheum Dis. 2011;70(10):1775–1781.
   PubMed Web of Science ®Google Scholar
• Vajapey SP, McKeon JF, Krueger CA, et al. Outcomes of total joint arthroplasty in patients with depression: a systematic review. J Clin Orthop Trauma. 2021;18:187–198.
   PubMedGoogle Scholar
• Marks R. Comorbid depression and anxiety impact hip osteoarthritis disability. Disabil Health J. 2009;2(1):27–35.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Carrino JA, Schnitzer TJ, et al. Long-term safety and efficacy of subcutaneous tanezumab versus nonsteroidal antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial. Arthritis Rheumatol. 2021;73(7):1167–1177.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Easton R, Pang S, et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA. 2019;322(1):37–48.
   PubMed Web of Science ®Google Scholar
• Berenbaum F, Blanco FJ, Guermazi A, et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann Rheum Dis. 2020;79(6):800–810.
   PubMed Web of Science ®Google Scholar
• Tive L, Bello AE, Radin D, et al. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res. 2019;12:975–995.
   PubMed Web of Science ®Google Scholar
• Berenbaum F, Schnitzer T, Kivitz A, et al. Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials. Int J Clin Pract. 2021;75(12):e14975.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Berenbaum F, Conaghan PG, et al. Single and composite endpoints of within-patient improvement in symptoms: pooled tanezumab data in patients with osteoarthritis. Rheumatol Ther. 2021;8(4):1759–1774.
   PubMed Web of Science ®Google Scholar
• McCaffrey N, Kaambwa B, Currow DC, et al. Health-related quality of life measured using the EQ-5D–5L: South Australian population norms. Health Qual Life Outcomes. 2016;14(1):133.
   PubMed Web of Science ®Google Scholar
• Berenbaum F, Schnitzer TJ, Kivitz AJ, et al. General safety and tolerability of subcutaneous tanezumab for osteoarthritis: a pooled analysis of three randomized, placebo-controlled trials. Arthritis Care Res (Hoboken). 2022;74:918–928.
   PubMed Web of Science ®Google Scholar
• Brown MT, Sandroni P, Low PA, et al. Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis. J Neurol Sci. 2022;434:120184.
   PubMed Web of Science ®Google Scholar
• Institute for Health Metrics and Evaluation. GBD results tool [Internet]. 2021. Available from: http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019-permalink/d780dffbe8a381b25e1416884959e88b.
   Google Scholar
• Hooten WM. Chronic pain and mental health disorders: shared neural mechanisms, epidemiology, and treatment. Mayo Clin Proc. 2016;91(7):955–970.
   PubMed Web of Science ®Google Scholar
• Dimitroulas T, Duarte RV, Behura A, et al. Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment. Semin Arthritis Rheum. 2014;44(2):145–154.
   PubMed Web of Science ®Google Scholar
• Clauw DJ, Hassett AL. The role of centralised pain in osteoarthritis. Clin Exp Rheumatol. 2017;35(Suppl 107(5)):79–84.
   PubMed Web of Science ®Google Scholar
• Vitiello MV, McCurry SM, Shortreed SM, et al. Short-term improvement in insomnia symptoms predicts long-term improvements in sleep, pain, and fatigue in older adults with comorbid osteoarthritis and insomnia. Pain. 2014;155(8):1547–1554.
   PubMed Web of Science ®Google Scholar
• Parmelee PA, Tighe CA, Dautovich ND. Sleep disturbance in osteoarthritis: linkages with pain, disability, and depressive symptoms. Arthritis Care Res (Hoboken). 2015;67(3):358–365.
   PubMed Web of Science ®Google Scholar
• Kroenke K, Shen J, Oxman TE, et al. Impact of pain on the outcomes of depression treatment: results from the RESPECT trial. Pain. 2008;134(1):209–215.
   PubMed Web of Science ®Google Scholar
• Gureje O. Treating chronic pain in the context of comorbid depression. Pain. 2008;134(1–2):3–4.
   PubMed Web of Science ®Google Scholar
• Holtz N, Hamilton DF, Giesinger JM, et al. Minimal important differences for the WOMAC osteoarthritis index and the forgotten joint score-12 in total knee arthroplasty patients. BMC Musculoskelet Disord. 2020;21(1):401.
   PubMed Web of Science ®Google Scholar
• Ehrich EW, Davies GM, Watson DJ, et al. Minimal perceptible clinical improvement with the Western Ontario and McMaster universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol. 2000;27(11):2635–2641.
   PubMed Web of Science ®Google Scholar
• Doganay Erdogan B, Leung YY, Pohl C, et al. Minimal clinically important difference as applied in rheumatology: an OMERACT Rasch working group systematic review and critique. J Rheumatol. 2016;43(1):194–202.
   PubMed Web of Science ®Google Scholar
• Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis. 2005;64(1):29–33.
   PubMed Web of Science ®Google Scholar
• Kim MS, Koh IJ, Choi KY, et al. The minimal clinically important difference (MCID) for the WOMAC and factors related to achievement of the MCID after medial opening wedge high tibial osteotomy for knee osteoarthritis. Am J Sports Med. 2021;49(9):2406–2415.
   PubMed Web of Science ®Google Scholar
• Zhang W, Robertson J, Jones AC, et al. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008;67(12):1716–1723.
   PubMed Web of Science ®Google Scholar
• Holmes RD, Tiwari AK, Kennedy JL. Mechanisms of the placebo effect in pain and psychiatric disorders. Pharmacogenomics J. 2016;16(6):491–500.
   PubMed Web of Science ®Google Scholar
• Colloca L, Benedetti F. Nocebo hyperalgesia: how anxiety is turned into pain. Curr Opin Anaesthesiol. 2007;20(5):435–439.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Shi SY, Li SJ, et al. Efficacy and safety of duloxetine on osteoarthritis knee pain: a meta-analysis of randomized controlled trials. Pain Med. 2015;16(7):1373–1385.
   PubMed Web of Science ®Google Scholar
• Weng C, Xu J, Wang Q, et al. Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2020;28(6):721–734.
   PubMed Web of Science ®Google Scholar
• Pfizer reports third-quarter 2021 results [Internet]. 2021. Available from: https://investors.pfizer.com/investor-news/press-release-details/2021/PFIZER-REPORTS-THIRD-QUARTER-2021-RESULTS/default.aspx.
   Google Scholar
• Lilly reports robust third-quarter 2021 financial results as pipeline success strengthens future growth potential [Internet]. 2021. Available from: https://investor.lilly.com/static-files/a0b77c52-a997-41c1-9534-5f465903a0b4.
   Google Scholar
• European Medicines Agency assessment report - Raylumis [Internet]. 2021. Available from: https://www.ema.europa.eu/en/documents/assessment-report/raylumis-epar-refusal-public-assessment-report_en.pdf.
   Google Scholar
• Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting Announcement [Internet] 2021. Available from: https://www.fda.gov/advisory-committees/arthritis-advisory-committee/march-24-25-2021-joint-meeting-arthritis-advisory-committee-and-drug-safety-and-risk-management
   Google Scholar